Alterations of A1 adenosine receptors in different mouse brain areas after pentylentetrazol-induced seizures, but not in the epileptic mutant mouse 'tottering'

Single and repeated Pentylentetrazol (PTZ)-induced convulsions are associated with significant changes of A1 adenosine receptors (detected using the radioligand [3H]cyclohexyladenosine, [3H]CHA) in 4 different brain areas of the mouse, namely cortex, hippocampus, cerebellum and striatum. In hippocampus and cerebellum, a rapid increase in [3H]CHA binding, by 26% and 30% respectively, was observed 1 h after a single PTZ convulsion. In striatum, on the contrary, a significant decrease by 30% in [3H]CHA binding was seen, whereas in cortex no significant change could be detected. After daily repeated PTZ convulsions, a significant increase of A1 receptors by 26% appeared also in cortex, while the changes of A1 receptors observed in the other brain areas after a single PTZ convulsion were maintained in almost the same range. All the alterations observed were due to changes of the total number of A1 receptors (Bmax) without changes in receptor affinity (Kd). A significant increase in the latency of PTZ seizure (time between the PTZ-injection and the beginning of the seizure) was also observed after repeated PTZ-induced convulsions at the time when the changes in A1 adenosine receptors were noted. Considered together, these results provide further evidence for an A1 receptor-mediated modulation of seizure susceptibility and indicate that specific brain areas may play different roles in this modulation. The binding of [3H]CHA to membranes from different cortical and subcortical areas of the epileptic mutant mouse 'tottering' was not different from that in control animals.     

Quantitative analysis of binding parameters of [3H]N-methylscopolamine in central nervous system of muscarinic acetylcholine receptor knockout mice

We have studied binding parameters (Kd, Bmax) of [3H]N-methylscopolamine ([3H]NMS) in various brain regions and spinal cord of wild-type (WT) and muscarinic acetylcholine receptor (mAChR) subtype (M1-M5) knockout (KO) mice. In the M1-M4 KO mice, the number of [3H]NMS binding sites (Bmax) was decreased throughout the central nervous system (CNS) with significant regional differences. Our results collectively suggest that M1 receptor was present in a relatively high density in the cerebral cortex and hippocampus, and the densities of M1 and M4 subtypes were highest in the corpus striatum. M2 receptor appeared to be the major subtype in the thalamus, hypothalamus, midbrain, pons-medulla, cerebellum and spinal cord. These findings may contribute significantly not only to the further understanding of the physiological roles of mAChR subtypes in the central cholinergic functions, but also to the development of selective therapeutic agents targeting specific subtype.     

Localisation of the adenosine uptake site in the human brain: a comparison with the distribution of adenosine Al receptors

Using quantitative receptor autoradiography we investigated the distribution of the adenosine uptake site labelled with [³H]NBTI in post-mortem human brain and compared its distribution with that of the A1 adenosine receptor labelled with [³H]CHA. The highest levels of [3H]NBTI binding were found in the cortex and striatum, with moderate levels in the hippocampus, globus pallidus, cerebellum and some midbrain and spinal cord nuclei. The distribution of A1 receptors and this adenosine uptake site differed in the hippocampus where A1 receptors were highest in CAI but the uptake site was low in CA1 and higher in the molecular layer of the dentate gyrus. These results define the anatomical distribution of the high affinity NBTI sensitive adenosine uptake site in the normal human brain.     

Reduction of A1 adenosine receptors in cortex, hippocampus and cerebellum in ageing mouse brain.

Age related changes in A1 adenosine receptor binding were investigated in mouse brain using the selective agonist, [3H]-cyclohexyladenosine ([3H]CHA). In the cortex, hippocampus and cerebellum of aged mice (28 months old), a significant decrease of about 44%, 50% and 12%, respectively, in [3H]CHA binding compared to young animals (3 months old) was observed. According to the Scatchard analysis of the binding data in the cortex, this decrease was due to a receptor density reduction and not to a Kd change. Since the weight and protein content of each tissue tested did not differ significantly between the old and the young animals, our findings may be partly explained by specific reductions of A1 receptors rather than a general cell degeneration in old age.     

Plasticity and ontogeny of the central 5-HT transporter: effect of neonatal 5,7-dihydroxytryptamine lesions in the rat.

5,7-Dihydroxytryptamine (5,7-DHT) is unique as a serotonin (5-HT) neurotoxin in that i.p. injection of neonatal rats increases concentrations of 5-HT in brainstem while depleting 5-HT in cortex, hippocampus and spinal cord. To study the mechanism of this effect we measured the 5-HT transporter or uptake site, a presynaptic marker, using [3H]paroxetine binding. There were significant regional differences in Bmax of vehicle-injected rats: brainstem, diencephalon > striatum, cortex, spinal cord > hippocampus, cerebellum. There were also regional differences in the ontogeny of bindings sites: at postnatal day 7, [3H]paroxetine sites were 39% of adult levels in cortex compared to 63% in brainstem. Thirty days after 100 mg/kg 5,7-DHT i.p., Bmax of [3H]paroxetine binding was significantly increased in brainstem (+67%) and diencephalon (+136%), whereas it decreased in cortex (-59%), hippocampus (-94%) and spinal cord (-99%), striatum (-41%) and cerebellum (-37%). KD remained unaltered. In dose-response studies (0-200 mg/kg), 50 mg/kg was the threshold dose for Bmax effects and 200 mg/kg was lethal. In weekly time-course studies, changes were apparent 1 week after 5,7-DHT lesions. Binding site increases in diencephalon and brainstem were not maximal until 3 weeks after injection, whereas percent decreases in cortical sites remained unchanged at each week studied. Lesion effects on the ontogeny of [3H]paroxetine binding sites were region-dependent: cortical sites continued to increase with age but spinal sites did not. There was no significant recovery in spinal cord.(ABSTRACT TRUNCATED AT 250 WORDS)     

Localization of L-glutamate receptors in rat brain by quantitative autoradiography

In vitro autoradiography was used to characterize and quantitatively map the sodium-independent binding of [3H]glutamate in rat brain. Measured in the presence of chloride, glutamate binding to frozen brain sections was specific, saturable, and reversible, with a Kd in the low micromolar range. At least two distinct binding sites were detected which had different affinities for quisqualic acid (0.7 microM and 1.2 mM). Autoradiograms revealed very high levels of binding in rostral forebrain areas, especially olfactory structures and frontal cortex. High levels of binding were found in sensory cortex, certain hippocampal subfields, caudate, lateral septum, and other limbic structures. Lowest levels were seen in globus pallidus, preoptic area, brainstem reticular formation, and spinal trigeminal nucleus. All other regions, including midbrain, thalamus, hypothalamus, and cerebellar cortex exhibited moderate levels of [3H]glutamate binding. Within the hippocampus glutamate binding was greatest in the inner two-thirds of the dentate molecular layer, subiculum, and CA1 stratum radiatum. CA3 was much less densely labeled; CA2 and CA4 were intermediate. Unlike cell layers in the cerebellum, hippocampal pyramidal and granule cell layers appeared mostly devoid of binding. The relationship of these binding sites to putative glutamate receptor subclasses and glutamatergic pathways is discussed.     

Effects of long-term theophylline treatment on adenosine A1-receptors in rat brain: autoradiographic evidence for increased receptor number and altered coupling to G-proteins

The effects of 2 weeks' treatment with theophylline (20 mg/kg i.p.) on the binding to adenosine A1-receptors was studied by autoradiography using the agonist [3H]N6-cyclohexyladenosine ([3H]CHA) and the antagonist [3H]8-cyclopentyl-1,3-dipropylxanthine ([3H]DPCPX) as ligands. A significant increase (10%) in [3H]CHA binding was measured only in the frontoparietal cortex. However, if the brain sections were incubated in the presence of 5 microM guanosine-5'-triphosphate (GTP), which by itself decreased binding by between 15 and 80% depending on the region, the increase in the frontoparietal cortex was larger (30%) and significant increases of the same magnitude were also seen in several other structures, e.g. the caudate putamen and the central gray matter of the midbrain. In some regions, for example the hippocampus and the cerebellar cortex, small or no increases were seen. GTP 100 microM practically eliminated [3H]CHA binding in both control and treated animals, suggesting that these receptors are all coupled to G-proteins. The binding of [3H]DPCPX was increased significantly only in the frontoparietal and striate cortex (5-10%). These results suggest that the theophylline treatment had little on the total receptor number but may have altered the coupling between A1-receptors and regulatory GTP-binding proteins.     

Cyclohexyladenosine binding in rat striatum

N6-Cyclohexyl-[3H]adenosine [( 3H]CHA) binds specifically to rat brain membranes prepared from the caudate-putamen complex with a Kd value of 2.50 +/- 0.39 nM and Bmax of 458 +/- 51 fmol/mg protein. Lesioning the nigrostriatal dopaminergic pathway using 6-hydroxydopamine failed to alter [3H]CHA binding characteristics. Intrastriatal kainate lesions reduced the binding capacity of [3H]CHA by 28% though this was not statistically significant (0.1 less than P greater than 0.05). In kainate-lesioned striata, however, 2-deoxyglucose uptake was reduced by only 39%.     

Inhibition of N6-[3H]cyclohexyladenosine binding by carbamazepine

The mechanism of action of carbamazepine (CBZ) (Tegretol), despite widespread use in the management of partial and tonic-clonic seizures in adults, is not completely understood. In animals, adenosine and adenosine analogues have anticonvulsant effects that may be due to interactions with central A1 adenosine receptors. CBZ (at therapeutically relevant concentrations) inhibits the binding of agonists and antagonists to brain A1 adenosine receptors, but whether as an agonist/antagonist is not clear. The adenosine agonist, N6-[3H]cyclohexyladenosine ([3H]CHA), binds to membranes from rat cortex and hippocampus at two nanomolar binding sites or states. To clarify the actions of carbamazepine at the A1 adenosine receptor, its inhibitory actions were compared with those of known adenosine agonists and xanthine antagonists using 0.1 nM[3H]CHA, in which almost all binding is to the higher affinity state, or 10 nM [3H]CHA, in which there is a substantial contribution of binding from both states. The ratios of the IC50 values (concentration that inhibits specific binding by 50%) at 10 nM [3H]CHA to the IC50 values at 0.1 nM [3H]CHA were 18-31 for the agonists and 4-10 for the xanthine antagonists. CBZ had a ratio of 3. The inhibitory effects of GTP on [3H]CHA binding were less in the presence of the adenosine agonist, 2-chloroadenosine than were inhibitory effects in the presence of the xanthine antagonist theophylline or CBZ in both cortex and hippocampus. These in vitro studies indicate that CBZ is an antagonist at A1 adenosine receptors in cerebral cortical and hippocampal membranes from rat brain. Agonist activity at A1 adenosine receptors would have been compatible with the sedative anticonvulsant effects of CBZ, but these data do not support a role of the anticonvulsant action of carbamazepine on A1 adenosine receptors in cerebral cortex or hippocampus.     

Regional central serotonin-2 receptor binding and phosphoinositide turnover in rats with 5,7-dihydroxytryptamine lesions

"Denervation supersensitivity" of serotonin (5-HT) receptors has been proposed to explain the behavioral supersensitivity to 5-hydroxytryptophan (5-HTP) which develops after lesions of indoleamine neurons with 5,7-dihydroxytryptamine (5,7-DHT). To examine the possible role of receptor recognition sites and second messenger activity in supersensitivity, we measured regional 5-HT2 receptor ligand binding and 5-HT-stimulated phosphoinositide turnover in adult rats with 5,7-DHT lesions made by intracisternal injection and their saline-treated controls. In [3H]ketanserin binding studies of fresh brain tissue two weeks after 5,7-DHT injection, there were no significant changes in frontal cortex, brainstem, or spinal cord in Bmax, Kd, or nH of 5-HT2 receptors, 5,7-DHT lesions did not affect basal levels of [3H]inositol phosphate (IP) accumulation but significantly increased 5-HT-stimulated [3H]IP accumulation in the brainstem (+27%) and cortex (+23%). Because brainstem rather than cortex is involved in 5-HTP-evoked myoclonus, increased 5-HT-stimulated phosphoinositide hydrolysis in brainstem following 5,7-DHT lesions in the rat may be relevant to serotonergic behavioral supersensitivity.     

Autoradiographic distribution of [3H]YM-09151-2, a high-affinity and selective antagonist ligand for the dopamine D2 receptor group,in the rat brain and spinal cord

We determined the regional distribution of the dopamine D₂ receptor group in the rat central nervous system by quantitative receptor autoradiography with a high-affinity and selective antagonist, [³H]YM-09151-2. Saturation and competition experiments demonstrated that the binding of [³H]YM-09151-2 to striatal sections was saturable (Bmax=37.3 fmol/section), of high affinity (Kd=0.315 nM), and was inhibited selectively by prototypic D₂ ligands. The anatomical localization of binding sites was determined by comparison of autoradiograms and the original ³H-ligand-exposed sections stained with cresyl violet. Very high levels of [³H] YM-09151-2 binding were found in the caudate-putamen, nucleus accumbens, tuberculum olfactorium and the insula of Calleja, to each of which midbrain dopaminergic neurons project densely. High levels of binding were also observed in other regiions rich in dopaminergic neurons and fibers including the glomerular layer of the olfactory bulb, the intermediate lobe of the pituitary, lateral septum, substantia nigra pars compacta, interfascicular nucleus, dorsal raphe nucleus, locus coeruleus, and nucleus of the solitary tract. Some regions poor in dopaminergi innervation, however, had high levels of [³H]YM-09151-2 binding including the molecular layer of gyrus dentatus, all layers of CA1 and the nonpyramidal layer of CA4 of hippocampus, and the deeper layer of medial entorhinal cortex. Motor neurons present in brainstem motor nuclei and spinal ventral horn were also strongly labeled. Neocortical, cerebellar, and thalamic regions had low levels of binding, except lobules 9–10 of the cerebellum, the olivary pretectal nucleus, zona incerta and lateral mammillary nucleus, in which moderate to high levels of binding were detected. Our findings concerning the widespread but region-specific localization of [³]YM-09151-2 binding sites in the brain and spinal cord may prove useful for analyzing varoius dopaminergic functions in the central nervous system. © 1994 Wiley-Liss, Inc.     

Nicotinic receptor binding sites in rat primary neuronal cells in culture: characterization and their regulation by chronic nicotine

We have characterized high affinity neuronal nicotinic acetylcholine receptors labeled by [3H]cytisine in primary neuronal cell cultures from fetal rat brains. After 15 days in culture, the highest density of [3H]cytisine binding sites (Bmax approximately 57 fmol/mg protein) was found in cells from the brainstem, which includes the following subcortical brain areas: the septum, thalamus, hypothalamus, midbrain, pons and medulla. A lower density of sites was found in cells from the cerebral cortex, hippocampus, and caudate nucleus. [3H]Cytisine binds to receptors in primary cells from the brainstem and cerebral cortex with a Kd of approximately 0. 5 nM, and the binding is inhibited by the agonists nicotine, acetylcholine, and epibatidine with IC50 values of 1 to 20 nM, and by carbachol and the antagonist dihydro-beta-erythroidine with IC50 values of 0.5 to 1.5 microM. Chronic treatment of neuronal cultures with nicotine for 7 days differentially affected the number of nicotinic receptors in cells from different brain areas; it significantly increased the number of nicotinic binding sites in cells from the cerebral cortex, hippocampus, and caudate, but not in cells from the brainstem. The nicotine-induced increase of receptors in cerebral cortical cultures was not blocked by either mecamylamine or dihydro-beta-erythroidine. These results indicate that primary cultures of rat neuronal cells provide a good model system in which to study and compare the properties and regulation of native neuronal nicotinic acetylcholine receptors.     

Heterogeneous distribution of adenosine transport sites labelled by [H]nitrobenzylthioinosine in rat brain: An autoradiographic and membrane binding study

A highly heterogeneous distribution of [3H]nitrobenzylthioinosine [( 3H]NBI) binding sites was observed using both autoradiographic and membrane binding methodology. Of the 24 brain regions examined in the radio-ligand binding studies, the highest levels of [3H]NBI sites were found in the thalamus, followed by midbrain, superior colliculus, olfactory cortex and hypothalamus. The thalamus contained over 5 times more sites than cerebellum which exhibited the lowest [3H]NBI binding levels. The results obtained from autoradiographic analysis agreed well with quantitative measurements and revealed that subnuclei of thalamus and hypothalamus as well as specific layers of the superior colliculus contained particularly high concentrations of [3H]NBI sites. When the [3H]NBI autoradiograms were compared with the distribution of adenosine deaminase in brain it was found that brain regions richest in neural elements immunoreactive for adenosine deaminase contained the greatest numbers of [3H]NBI sites. In contrast, a poor correlation was found between the distribution of [3H]NBI binding and adenosine receptors labelled with [3H]cyclohexyladenosine. The co-localization of [3H]NBI binding and adenosine deaminase in brain indicates the existence of neural systems having a high capacity to take up and metabolize adenosine.     

The ontogeny of [3H]5-hydroxytryptamine binding in the lamb: effects of in vivo thyroidectomy

The effects of congenital hypothyroidism in the late gestation ovine fetus include changes in serotonin concentrations in specific brain areas. To investigate possible ontogenic patterns of changes in 5-HT receptor function, we studied the binding characteristics of [3H]5-HT in the midbrain, hypothalamus and cerebral cortex in the late gestation ovine fetus and young lamb. We compared the binding characteristics of control fetuses to those of thyroidectomized fetuses, with or without thyroxine replacement therapy. In each of the areas examined, age-dependent changes in the receptor density (Bmax) for [3H]5-HT was observed. In cerebral cortex, Bmax was constant from 120 days gestation through the early neonatal period and increased significantly only at 25-30 days after birth. In hypothalamus, [3H]5-HT binding density decreased late in gestation (140-145 days) with a return after birth to values comparable to those at 120-125 and 130-135 days gestation. The midbrain also exhibited a significant age-dependent pattern of altered receptor density with a decrease in the 130-135 and 140-145 day gestational age groups compared to both younger and older lambs. In contrast, the affinity constant (Kd) for [3H]5-HT did not change over the ages evaluated in cerebral cortex or hypothalamus. In the midbrain, however, there was a significant increase in Kd at 1-5 days after birth compared to all other age groups. The ability of fetal thyroidectomy, with or without thyroxine replacement therapy, to alter patterns of [3H]5-HT binding was also tested.(ABSTRACT TRUNCATED AT 250 WORDS)     

Persistent upregulation of brain adenosine receptors in response to chronic carbamazepine treatment

Chronic carbamazepine treatment for a period of 2 weeks caused a highly significant increase in brain adenosine receptors in the rat. The carbamazepine was administered in food pellets in a diet that achieved clinically relevant total plasma concentrations of carbamazepine and its active-10,11-epoxide metabolite. Of the several brain areas examined, the cerebral cortex and hippocampus exhibited the most robust increases in [3H]cyclohexyladenosine (CHA) binding. Increases of 35-40% were observed in these brain regions whereas an 8-10% increase was seen in the cerebellum. The carbamazepine induced increase in brain adenosine receptors in all these areas persisted unabated at 1 and 5 days as well as 2, 4, and 8 weeks following termination of carbamazepine treatment, suggesting a relatively permanent alteration of the adenosine receptor by this drug.     

Quantitative autoradiographic analysis of the distribution of [3H]muscimol binding to GABA receptors in chick brain

Quantitative receptor autoradiography was used to investigate the distribution of high-affinity GABA receptors (GABAA) in left and right hemispheres of the brains of 3-week-old chicks. The receptors were labelled with the potent GABA agonist [3H]muscimol. High levels of [3H]muscimol labelling were found throughout the fore-, mid-, and hindbrain, though considerable variation was found in different regions. In the telencephalon the highest concentration of specific binding was found in the hyperstriatum ventrale followed by the neostriatum, and then the lobus parolfactorius of the paleostriatal complex, whilst in the diencephalon highest levels of labelling were present in the infundibulum. In the midbrain distinct lamination was observed in the high levels of [3H]muscimol binding in the optic tectum and in the hind brain the highest density of labelling occurred in the granular layers of the cerebellum. Levels of labelling were generally low in the brainstem regions. The distribution of [3H]muscimol binding in the optic tectum and in the hind brain the highest density of labelling occurred in the granular layers of the cerebellum. Levels of labelling were generally low in the brainstem regions. The distribution of [3H]muscimol binding sites is in good agreement with our previous work on the distribution of GABA-immunoreactivity in the chick brain.     

Neuroimaging of the serotonin reuptake site requires high-affinity ligands

Numerous attempts have been made to develop suitable radiolabeled tracers for positron emission tomography or single photon emission computed tomography imaging of the serotonin transporter (SERT), but most often, negative outcomes are reported. The aim of this study is to define characteristics of a good SERT radioligand and to investigate species differences. We examined seven different selective serotonin reuptake inhibitors (SSRIs) and that except for one all have been previously tested as emission tomography ligands. The outcome of the ligands as emission tomography tracers was compared in relation with receptor density (Bmax) and/or ligand affinity (Kd) in rat and monkey cerebrum and cerebellum (reference region) membranes. [3H]-(S)-Citalopram and [3H]-(+)-McN5652 display statistically significantly lower affinity, whereas [3H]paroxetine displays statistically significantly higher affinity for SERT in monkey cortex when compared with the rat cerebrum. The affinity of [3H]MADAM, [123I]ADAM, and [11C]DASB for SERT obtained with rat cerebrum and monkey cortex are similar. In monkey cortex, Kd and Bmax could not be determined with [3H]fluoxetine. Of the seven SSRIs, [3H]-(S)-citalopram, [3H]MADAM, and [11C]DASB displayed significant specific binding to SERT in monkey cerebellum, with Bmax cortex:cerebellum ratios being 17, 3, and 4, respectively. In rat brain tissue the ratios were 12, 6, and 3, respectively. In conclusion, it can be estimated that imaging of the human SERT in a high-density region requires radioligands with Kd values between 0.03 and a maximum of 0.3 nM (at 37 degrees C). The differential specific cerebellar binding raises the question of the suitability of cerebellum as a reference region for nonspecific binding.     

Visualization of neurokinin-3 receptor sites in rat brain using the highly selective ligand [3H]senktide.

The autoradiographic distribution of the neurokinin (NK)-3 receptor sub-type was visualized in the rat brain using [3H]senktide, a highly selective ligand, [3H]Senktide apparently binds to a single class of high affinity (Kd = 2.8 +/- 1.0 nM), low capacity (Bmax = 31.2 +/- 3.0 fmol/mg protein) sites in rat brain cortex. The ligand selectivity pattern reveals that eledoisin and senktide are potent competitors of both [3H]senktide and [125I]Bolton-Hunter eledoisin binding sites demonstrating the NK-3 nature of these sites. Autoradiographic data show that [3H]senktide binding sites are concentrated in mid-cortical layers, supraoptic nucleus, zona incerta, basolateral nucleus of the amygdala and interpeduncular nucleus. Much lower densities of binding are seen in most other areas such as the caudate-putamen and cerebellum. This distribution is similar, but not identical, to that previously reported for NK-3 sites using less selective ligands. It is most likely because less selective probes also bind to other classes of NK receptors. The higher selectivity of [3H]senktide is thus an important advantage for the precise characterization of NK-3 receptor binding parameters.     

Noradrenergic innervation does not affect chronic regulation of [125I]pindolol receptors in fetal rat brain transplants or host neocortex

Fetal (E15-16) somatosensory cortex (n = 15) or cerebellum (n = 9) were placed into the somatosensory cortex (SmI) of adult rat hosts to study the relative importance of tissue origin versus host milieu on graft beta-adrenoceptor regulation. Autoradiographic studies of [125I]pindolol ([125I]pin) binding in the presence of 3 microM serotonin were performed as an index of beta-receptor binding in both intact hosts and those with ipsilateral locus coeruleus (LC) lesions and/or ipsilateral superior cervical ganglionectomy. [125I]pin binding within fetal grafts was highly variable with areas of highest specific binding in cortical grafts (Kd = 209 +/- 30 pM, Bmax = 106 +/- 7 (fmol/mg protein) being comparable to host cortex (Kd = 211 +/- 41 pM, Bmax = 111 +/- 9 fmol/mg protein). Average total binding in whole cortical grafts was 73% and in cerebellar grafts was 60% of that in comparable adult cortex. Host cortex had 66-73% and cerebellum had 4-8% beta 1-receptors while cortical grafts had 59% and cerebellar grafts had 43% beta 1-receptors as determined by competitive binding with ICI 89406 and 118551. Noradrenergic fibers derived from both the host LC and superior cervical ganglion grew into fetal cortical grafts. Binding to high affinity uptake sites ([3H]desmethylimipramine, [3H]DMI) on noradrenergic terminals in cerebellar grafts was 28% higher than that in cortical grafts; superior cervical ganglionectomy decreased [3H]DMI binding in cortical grafts by 37% but had no effect on cerebellar grafts. Neither ganglionectomy nor LC lesions affected total specific binding or binding to beta-receptor subtypes in the grafts or host cortex 3-6 months after removal. Therefore, anatomic site of origin appeared to be the predominant factor in determining the development of beta-adrenoceptors in fetal cortical tissue. In ectopically placed cerebellar grafts, beta-receptor subtypes did not develop comparably to host cerebellar receptors suggesting that host milieu may be of critical importance in receptor development in this tissue.     

Localization of [3H]cyclohexyladenosine and [3H]nitrobenzylthioinosine binding sites in rat striatum and superior colliculus

The localization of adenosine receptors labelled with [3H]cyclohexyladenosine ([3H]CHA) and adenosine transport sites labelled with [3H]nitrobenzylthioinosine ([3H]NBI) was examined in striatum and superior colliculus (SC) using radioligand binding and lesioning methods. Striatal kainic acid lesions significantly reduced the number (Bmax) of a single class of high affinity binding sites for [3H]CHA by 50% and that for [3H]NBI by 15% without altering Kd values for either ligand. In SC, enucleations significantly reduced both high and low affinity [3H]CHA binding sites by about 60% while levels of [3H]NBI binding were unaffected. Thus, adenosine receptors are present on striatal interneurons and retinal projections to the SC and some [3H]NBI binding sites are located on striatal interneurons.